Bright-light therapy (BLT) is established as the treatment of choice for seasonal affective disorder/winter type (SAD). In the last two decades, the use of BLT has expanded beyond SAD: there is evidence for efficacy in chronic depression, antepartum depression, premenstrual depression, bipolar depression and disturbances of the sleep-wake cycle. Data on the usefulness of BLT in non-seasonal depression are promising; however, further systematic studies are still warranted. In this review, the authors present a comprehensive overview of the literature on BLT in mood disorders. The first part elucidates the neurobiology of circadian and seasonal adaptive mechanisms focusing on the suprachiasmatic nucleus (SCN), the indolamines melatonin and serotonin, and the chronobiology of mood disorders. The SCN is the primary oscillator in humans. Indolamines are known to transduce light signals into cells and organisms since early in evolution, and their role in signalling change of season is still preserved in humans: melatonin is synthesized primarily in the pineal gland and is the central hormone for internal clock circuitries. The melatonin precursor serotonin is known to modulate many behaviours that vary with season. The second part discusses the pathophysiology and clinical specifiers of SAD, which can be seen as a model disorder for chronobiological disturbances and the mechanism of action of BLT. In the third part, the mode of action, application, efficacy, tolerability and safety of BLT in SAD and other mood disorders are explored.

PurposeTo compare the quality of four OCT-angiography(OCT-A) modules.MethodThe retina of nineteen healthy volunteers were scanned with four OCT-devices (Topcon DRI-OCT Triton Swept-source OCT, Optovue RTVue-XR, a prototype Spectralis OCT2, Heidelberg-Engineering and Zeiss Cirrus 5000-HD-OCT). The device-software generated en-face OCT-A images of the superficial (SCP) and deep capillary plexuses (DCP) were evaluated and scored by 3 independent retinal imaging experts. The SCP vessel density was assessed using Angiotool-software. After the inter-grader reliability assessment, a consensus grading was performed and the modules were ranked based on their scoring.ResultsThere was no significant difference in the vessel density among the modules (Zeiss 48.7±4%, Optovue 47.9±3%, Topcon 48.3±2%, Heidelberg 46.5±4%, p = 0.2). The numbers of discernible vessel-bifurcations differed significantly on each module (Zeiss 2±0.9 bifurcations, Optovue 2.5±1.2, Topcon 1.3±0.7 and Heidelberg 0.5±0.6, p≤0.001). The ranking of each module differed depending on the evaluated parameter. In the overall ranking, the Zeiss module was superior and in 90% better than the median (Bonferroni corrected p-value = 0.04). Optovue was better than the median in 60%, Topcon in 40% and Heidelberg module in 10%, however these differences were not statistically significant.ConclusionEach of the four evaluated OCT-A modules had particular strengths, which differentiated it from their competitors.

Analysis of resting-state networks using fMRI usually ignores high-frequency fluctuations in the BOLD signal – be it because of low TR prohibiting the analysis of fluctuations with frequencies higher than 0.25 Hz (for a typical TR of 2 s), or because of the application of a bandpass filter (commonly restricting the signal to frequencies lower than 0.1 Hz). While the standard model of convolving neuronal activity with a hemodynamic response function suggests that the signal of interest in fMRI is characterized by slow fluctuation, it is in fact unclear whether the high-frequency dynamics of the signal consists of noise only. In this study, 10 subjects were scanned at 3 T during 6 min of rest using a multiband EPI sequence with a TR of 354 ms to critically sample fluctuations of up to 1.4 Hz. Preprocessed data were high-pass filtered to include only frequencies above 0.25 Hz, and voxelwise whole-brain temporal ICA (tICA) was used to identify consistent high-frequency signals. The resulting components include physiological background signal sources, most notably pulsation and heart-beat components, that can be specifically identified and localized with the method presented here. Perhaps more surprisingly, common resting-state networks like the default-mode network also emerge as separate tICA components. This means that high-frequency oscillations sampled with a rather T1-weighted contrast still contain specific information on these resting-state networks to consistently identify them, not consistent with the commonly held view that these networks operate on low-frequency fluctuations alone. Consequently, the use of bandpass filters in resting-state data analysis should be reconsidered, since this step eliminates potentially relevant information. Instead, more specific methods for the elimination of physiological background signals, for example by regression of physiological noise components, might prove to be viable alternatives.

Imaging the amygdala with functional MRI is confounded by multiple averse factors, notably signal dropouts due to magnetic inhomogeneity and low signal-to-noise ratio, making it difficult to obtain consistent activation patterns in this region. However, even when consistent signal changes are identified, they are likely to be due to nearby vessels, most notably the basal vein of rosenthal (BVR). Using an accelerated fMRI sequence with a high temporal resolution (TR = 333 ms) combined with susceptibility-weighted imaging, we show how signal changes in the amygdala region can be related to a venous origin. This finding is confirmed here in both a conventional fMRI dataset (TR = 2000 ms) as well as in information of meta-analyses, implying that “amygdala activations” reported in typical fMRI studies are likely confounded by signals originating in the BVR rather than in the amygdala itself, thus raising concerns about many conclusions on the functioning of the amygdala that rely on fMRI evidence alone.

A majority of patients show MA after long-term anti-VEGF treatment. Reticular pseudodrusen (RPD), IRC and PVD but not number of injections or treatment duration seem to be associated with the MA size.